OncoSec Medical (FRA:ONMA) Change In Receivables : €0.00 Mil (TTM As of Jan. 2023)

View and export this data going back to 2015. Start your Free Trial

What is OncoSec Medical Change In Receivables?

OncoSec Medical's change in receivables for the quarter that ended in Jan. 2023 was €0.00 Mil. It means OncoSec Medical's Accounts Receivable stayed the same from Oct. 2022 to Jan. 2023 .

OncoSec Medical's change in receivables for the fiscal year that ended in Jul. 2022 was €0.00 Mil. It means OncoSec Medical's Accounts Receivable stayed the same from Jul. 2021 to Jul. 2022 .

OncoSec Medical's Accounts Receivable for the quarter that ended in Jan. 2023 was €0.00 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. OncoSec Medical's liquidation value for the three months ended in Jan. 2023 was €-9.91 Mil.

OncoSec Medical Change In Receivables Historical Data

The historical data trend for OncoSec Medical's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

OncoSec Medical Change In Receivables Chart

OncoSec Medical Annual Data

Trend

Jul13

Jul14

Jul15

Jul16

Jul17

Jul18

Jul19

Jul20

Jul21

Jul22

Change In Receivables

Get a 7-Day Free Trial

OncoSec Medical Quarterly Data
	Apr18	Jul18	Oct18	Jan19	Apr19	Jul19	Oct19	Jan20	Apr20	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23
Change In Receivables	Get a 7-Day Free Trial															-	-	-	-	-

OncoSec Medical Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Jan. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.00 Mil.

OncoSec Medical (FRA:ONMA) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

OncoSec Medical's Days Sales Outstanding for the quarter that ended in Jan. 2023 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	0	/	0	*	91
=

2. In Ben Graham's calculation of liquidation value, OncoSec Medical's accounts receivable are only considered to be worth 75% of book value:

OncoSec Medical's liquidation value for the quarter that ended in Jan. 2023 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	3.418	-	13.324	+	0.75 * 0	+	0.5 * 0
=	-9.91

OncoSec Medical Change In Receivables Related Terms

Thank you for viewing the detailed overview of OncoSec Medical's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

OncoSec Medical (FRA:ONMA) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » OncoSec Medical Inc (FRA:ONMA) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

ONCSQ:USA

Address

24 North Main Street, Pennington, NJ, USA, 08534

Website

https://www.oncosec.com

OncoSec Medical Inc is a healthcare sector company. It is focused on designing, developing and commercializing gene therapies, therapeutics, and medical approaches to stimulate an anti-tumor immune response for the treatment of cancer. The company's lead product candidate, ImmunoPulse IL-12, consists of a plasmid construct encoding the proinflammatory cytokine, IL-12, which is delivered into the tumor through in vivo electroporation. In addition, it is pursuing ImmunoPulse IL-12 monotherapy in patients with triple-negative breast cancer.

OncoSec Medical (FRA:ONMA) Headlines

No Headlines